Daniel Jenny

Daniel Jenny specialises in M&A transactions, capital markets, corporate restructurings, general corporate and commercial matters (e.g. joint ventures, shareholders' agreements). He is active in various sectors, including private equity, TMC and Life Science & Healthcare. Daniel Jenny is also an expert in corporate governance, in particular concerning questions on directors' liability. 

• Everbridge | Advised client on the acquisition of Techwan SA
• Apotal Group | Advised client on the sale of its online pharmacy's mail-order business and diabetes arm to Zur Rose-Group
• Advised client on the restructuring of a group company (interim debt restructuring moratorium of the insolvent company and subsequent acquisition of the viable parts of the insolvent company by a newly-formed entity)
• capiton/CymbiQ Group AG | Advised client on the acquisition of Aspectra AG
• EMS-Group | Advised client on the sale of EMS-PATVAG (s.r.o.)
• ABB | Advised client on the acquisition of Cassantec
• Showa Denko | Advised client on the acquisition of the ILAG Group from Helvetica Capital (with City-Yuwa Partners, Tokyo)
• Bruker | Advised client on the acquisition of PMOD Technologies LLC

• Capital markets: Equity
• M&A
• Private equity
• Restructuring and insolvency

• Consumer goods and services
• Healthcare
• Industrials
• Insurance
• Pharma and life sciences
• Tech and telecoms

• 2007

• Zürcher Anwaltsverband (ZAV); SChweizerischer Anwaltsverband (SAV); SECA

• 2012 Doktorat, Dr. iur., summa cum laude, Universität Zürich, Prof. Walther Hug Preis
• 2010 Master of Laws, LL.M ,New York University School of Law, Half Tuition Dean's Graduate Award
• 2007 Anwaltspatent
• 2004 Visiting Scholar, Max Planck Institut für ausländisches und internationales Privatrecht, Hamburg
• 2003 Rechtsstudium, lic. iur., magna cum laude, Universität Zürich